- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Summit Therapeutics PLC (SMMT)
Track today's live Summit Therapeutics PLC (SMMT) share price, performance and key data on this page with our current NASDAQ:SMMT stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Summit Therapeutics PLC share price on the NASDAQ exchange. Use the dropdown to switch exchange for the SMMT share price, head to our technical summary section, which provides analysis on Summit Therapeutics PLC share price buy/sell indicators using real-time data (or discuss the Summit Therapeutics PLC (SMMT) stock price today with other investors in the Summit Therapeutics PLC NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ:SMMT share price (ISIN: US86627T1088) to enhance your trading decisions with our free investment tools and resources.
What Is the Summit Therapeutics PLC Share Price Today?
The Summit Therapeutics PLC share price today is 13.110.
What Is the Stock Symbol for Summit Therapeutics PLC
The stock symbol (or 'ticker') for Summit Therapeutics PLC is "SMMT."
What Stock Exchange Does Summit Therapeutics PLC Trade On?
Summit Therapeutics PLC is listed and trades on the NASDAQ stock exchange.
Is Summit Therapeutics PLC a Good Stock to Buy?
Determining whether Summit Therapeutics PLC (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current NASDAQ:SMMT share price (ISIN: US86627T1088) to enhance your trading decisions with our free investment tools and resources.
What Is the Summit Therapeutics PLC Share Price Today?
The Summit Therapeutics PLC share price today is 13.110.
What Is the Stock Symbol for Summit Therapeutics PLC
The stock symbol (or 'ticker') for Summit Therapeutics PLC is "SMMT."
What Stock Exchange Does Summit Therapeutics PLC Trade On?
Summit Therapeutics PLC is listed and trades on the NASDAQ stock exchange.
Is Summit Therapeutics PLC a Good Stock to Buy?
Determining whether Summit Therapeutics PLC (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12.920
13.390
52 wk Range
12.070
30.050
SMMT is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12.92013.390
52 wk Range
12.07030.050
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
SMMT Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
28.559
Upside
+117.84%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Neutral
Analyst Ratings
10 Buy
6 Hold
1 Sell
Ratings:
17 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 28.559
(+117.84% Upside)
Summit Therapeutics PLC Earnings Call Summary for Q2/2026
- Summit posted Q2 loss of $0.37/share vs. $0.28 expected, a 32.6% miss; shares fell 4.6% after hours despite 1.6% regular-session gain.
- Cash rose to $690.7M from $598.7M in Q1 via $231M ATM raise; operating expenses jumped 24% to $151.8M on three Phase III trials.
- Updated HARMONi survival data showed 0.76 hazard ratio; company maintains Nov. 14, 2026 PDUFA date for ivonescimab in EGFR-mutated NSCLC.
- Key milestones: HARMONi-3 squamous PFS data H2 2026, OS interim analysis H1 2027, Arcus collaboration data mid-2027.
- Filed new $380M ATM facility for financing flexibility; commercial launch prep underway with leadership in place, field force hiring near approval.
Last Updated: 23/07/2026, 22:50
Read Full TranscriptEarnings
Latest Release
23/07/2026
EPS / Forecast
-0.37 / -0.28
Revenue / Forecast
-- / --
Compare SMMT to Peers and Sector
Metrics to compare | SMMT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSMMTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −12.2x | −3.6x | −0.3x | |
PEG Ratio | 1.16 | −0.05 | 0.00 | |
Price/Book | 16.6x | 2.3x | 2.6x | |
Price / LTM Sales | - | 34.2x | 3.1x | |
Upside (Analyst Target) | 161.5% | 106.2% | 48.5% | |
Fair Value Upside | Unlock | −12.2% | 6.3% | Unlock |
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Summit Therapeutics PLC (NASDAQ: SMMT) Share Price Today?
The Summit Therapeutics PLC stock price today is 13.110 USD.
What Stock Exchange Does Summit Therapeutics PLC (SMMT) Trade On?
Summit Therapeutics PLC is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Summit Therapeutics PLC?
The stock symbol (also called a 'ticker') for Summit Therapeutics PLC is "SMMT."
What Is the Current Summit Therapeutics PLC Market Capitalisation?
As of today, Summit Therapeutics PLC (NASDAQ: SMMT) market cap is 10.460B USD.
What Is Summit Therapeutics PLC's (SMMT) Earnings Per Share (TTM)?
The Summit Therapeutics PLC EPS is currently -1.118 (Trailing Twelve Months).
When Is the Next Summit Therapeutics PLC Earnings Date?
Summit Therapeutics PLC's next earnings report will be released on 11/11/2026.
Is SMMT a Buy or Sell From a Technical Analyst Perspective?
Based on today's Summit Therapeutics PLC moving averages and other technical indicators, the daily buy/sell signal for SMMT stock is Strong Sell.
How Many Times Has Summit Therapeutics PLC Stock Split?
Summit Therapeutics PLC has split 0 times. (See the SMMT stock split history page for full effective split date and price information.)
How Many Employees Does Summit Therapeutics PLC Have?
Summit Therapeutics PLC has 265 employees, based on their latest Companies House report.
What is the current trading status of Summit Therapeutics PLC (NASDAQ: SMMT)?
As of 20/08/2026, Summit Therapeutics PLC (SMMT) is trading at a share price of 13.110 USD, with a previous close of 13.110 USD. The stock has fluctuated within a day range of 12.920 USD to 13.390 USD, while its 52-week range spans from 12.070 USD to 30.050 USD.
What Is Summit Therapeutics PLC (SMMT) Price Target According to Analysts?
The average 12-month price target for Summit Therapeutics PLC is 28.559 USD, with a high estimate of 41.91836735 USD and a low estimate of 9.88027211 USD. 10 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +117.84% Upside potential.
What Is the SMMT Premarket Price?
SMMT's last pre-market stock price is 13.390 USD. The pre-market share volume is 11,520.000, and the stock has decreased by 0.280, or 2.140%.
What Is the SMMT After Hours Price?
SMMT's last after hours stock price is 13.220 USD, the stock has decreased by 0.110, or 0.840%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.